Purpose: To introduce Reata, and provide an overview of the development history and biology of Bardoxolone methyl, the compound to be studied in Reata’s Alport Syndrome program. Additionally, there will be time at the end for Q&A.
Who: This event is intended for any interested Alport Syndrome patients and/or family members and will be hosted by Reata’s Chief Development Officer, Keith Ward.
When: February 8, 2017 at 8:00 pm CT, and February 9, 2017 at 12:00 pm CT.
You may also contact Hanh Nguyen ([email protected]) to register for one of the webexes.